Perrigo Company plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRGO research report →
Range $20 – $54
Price Chart
About the company
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
- CEO
- Albert A. Manzone
- IPO
- 1991
- Employees
- 8,100
- HQ
- Dublin, DU, IE
Get TickerSpark's AI analysis on PRGO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.21B
- P/E
- -1.33
- Fwd P/E
- 6.97
- PEG
- 0.00
- P/S
- 0.57
- P/B
- 0.97
- EV/EBITDA
- -4.85
- Div Yield
- 6.85%
- Gross Margin
- 32.33%
- Op Margin
- 4.05%
- Net Margin
- -43.27%
- ROE
- -68.13%
- ROIC
- 2.55%
Latest fiscal year · YoY change
- Revenue
- $4.25B-2.8%
- Gross Profit
- $1.49B-3.1%
- Op Income
- $343.30M
- Net Income
- $-1,425,400,000-729.7%
- EPS
- $-10.29-723.2%
- OCF Growth
- -34.3%
- FCF Growth
- -40.7%
- 52W High
- $17.07
- 52W Low
- $9.23
- 50D MA
- $15.32
- 200D MA
- $12.56
- Beta
- 0.54
- RSI (14)
- 49
- Avg Volume
- 2.55M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Perrigo said Q3 showed sequential improvement in execution and margins, but sales still declined and the company trimmed its 2026 outlook on cautious retailer inventory and weak Europe.· November 4, 2026
- Core sales fell 1.7% year over year, but the decline improved sequentially from the first half of 2026.
- Core adjusted operating margin rose to 14.3%, continuing a quarter-by-quarter improvement this year.
- Perrigo sold Dermacosmetics and agreed to divest infant formula, simplifying the portfolio and improving the margin profile.
- U.S. store brand OTC volume grew 2% and Perrigo gained 30 basis points of share; key European brands grew 6.5% and gained 80 basis points of share.
- Management said e-commerce is a growing opportunity, with U.S. e-commerce volume up nearly 15% year to date and representing 22% of U.S. volume, up from about 13% in 2022.
Third quarter all-in net sales were $989 million, down 5.2% year over year; core net sales declined 1.7% and core organic net sales declined 1.1%. Core adjusted gross margin was 37.9%, down 140 basis points, and core adjusted operating margin was 14.3%, down 210 basis points. Core adjusted EPS was $0.61, down $0.06, while all-in adjusted diluted EPS was $0.60, down $0.20. Cash from operating activities was $96 million, capital expenditures were $18 million, cash and equivalents were $437 million, and total debt was $3.3 billion. For 2026, Perrigo now expects core reported net sales to decline 2.5%-3.6%, core organic sales to decline 2.7%-3.8%, core adjusted gross margin of 37.5%-38.5%, core adjusted operating margin of 14%-15%, and core adjusted EPS of $2.15-$2.35. On an all-in basis excluding infant formula, it expects net sales to decline 4.6%-5.7%, adjusted gross margin of 37.8%-38.8%, adjusted operating margin of 14.3%-15.3%, and adjusted EPS of $2.25-$2.45. Management also guided to year-end net leverage of about 4.0x adjusted EBITDA, net interest expense of about $162 million, an adjusted tax rate of about 14%, and low-to-mid-60% cash from operating activities as a percentage of adjusted net income.
Albert Manzone’s message was that Perrigo has strong assets but has been held back by complexity, and his focus is on simplifying the company and concentrating capital and management attention where Perrigo has the best right to win. He emphasized the Three-S plan, the sale of infant formula, and the ongoing oral care review as part of a more disciplined portfolio strategy. His tone was constructive and confident, highlighting share gains, improving execution, and e-commerce as key growth levers.
Eduardo Bezerra said Q3 core net sales declined 1.7% and core adjusted operating margin reached 14.3%, with lower sales, unfavorable mix, and higher advertising/promotion costs partly offset by Operational Enhancement Program savings of $19 million. He said core adjusted gross margin was 37.9%, all-in adjusted gross margin was 36.3%, and tariff benefits were about $4.5 million in the quarter. On cash, he cited $96 million of operating cash flow, $18 million of capex, $437 million of cash, and $3.3 billion of debt, and said the infant formula divestiture should reduce future capital requirements and be deployed toward growth, debt reduction, and capital allocation discipline.
Analysts pressed management on the strategic path after the infant formula sale, including whether oral care will still be sold and whether any other divestitures are likely. Manzone said oral care review is ongoing and that infant formula and oral care are currently the two assets under review, while stressing the priority is simplification, margin improvement, and disciplined capital allocation. Questions also focused on 2027, tariff benefits, and cough-and-cold inventory; management said tariff benefits were about $4.5 million in Q3, that one-time tariff help will not repeat, and that retailer inventories were more cautious ahead of a season whose timing may shift into Q4 or Q1.
Management pointed to sequential improvement in sales trends, margins, and execution, with core net sales declines narrowing and core adjusted operating margin rising each quarter this year. Perrigo also said it is gaining share in U.S. store brand OTC and in key European brands, with e-commerce and innovation seen as meaningful growth opportunities. The infant formula divestiture was framed as simplifying the business and improving the margin profile while freeing capital for core priorities.
The company still faces weak consumer conditions, especially in Europe, plus more measured retailer inventory positioning ahead of cough-and-cold season and lower contract manufacturing volumes. Gross margin and EPS were down year over year, and management warned that tax-rate normalization, the loss of tariff benefits, and inflation will create pressure in 2027. The outlook was cut despite early signs of better illness trends, showing management remains cautious about the timing and strength of replenishment.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 138.80M
- Float Shares
- 138.10M
of shares held by institutions
354 13F filers
Buy/sell ratio 1.75. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for PRGO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Michael T. McCaulHouse · TX10 | Sell | Jun 2, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 29, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 5, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 22, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 22, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 23, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 23, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 1, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 2, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 1, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 5, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 29, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 28, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jun 28, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 23.39M | ▲ 685.40K |
| Vanguard Group Inc | 14.98M | ▲ 1.10M |
| Neuberger Berman Group LLC | 10.33M | ▼ 348.56K |
| Vanguard Portfolio Management LLC | 9.07M | ▲ 25.79K |
| State Street Corp | 8.64M | ▲ 109.36K |
| Vanguard Capital Management LLC | 6.27M | ▲ 23.59K |
| Fmr LLC | 6.25M | ▲ 5.85M |
| Fuller & Thaler Asset Management, Inc. | 5.43M | ▼ 2.06M |
| Invesco Ltd. | 5.03M | ▼ 840.14K |
| Wellington Management Group Llp | 4.87M | ▲ 4.87M |
| Dimensional Fund Advisors LP | 4.61M | ▼ 853.65K |
| Menora Mivtachim Holdings Ltd. | 4.39M | 0 |
Held by 292 ETFs
Biggest fund positions in PRGO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 11, 26 | Parker Geoffrey M. | other | 1,263 |
| Sep 11, 26 | Parker Geoffrey M. | other | 607 |
| Sep 11, 26 | Parker Geoffrey M. | other | 1,263 |
| Sep 11, 26 | Alford Bradley A | other | 1,263 |
| Sep 11, 26 | Alford Bradley A | other | 607 |
| Sep 11, 26 | Alford Bradley A | other | 2,059 |
| Sep 11, 26 | Alford Bradley A | other | 1,263 |
| Sep 9, 26 | Ball David | other | 7,701 |
| Sep 9, 26 | Ball David | other | 2,784 |
| Sep 9, 26 | Ball David | other | 7,701 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRGO coverage
Recent articles, reports, and earnings notes.
No research on PRGO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRGO report →Perrigo to Attend the Jefferies Miami Consumer Conference
prnewswire.com · Nov 11
Perrigo Q3 Earnings Call Highlights
marketbeat.com · Nov 8
Perrigo: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 6
Perrigo Company plc (PRGO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Perrigo (PRGO) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Nov 4
Perrigo (PRGO) Surpasses Q3 Earnings Estimates
zacks.com · Nov 4
Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations
prnewswire.com · Nov 4
Perrigo Announces Quarterly Dividend
prnewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.